• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2021 年 1 月至 11 月，爱沙尼亚、爱尔兰、卢森堡和斯洛伐克的监测数据分析显示，接种疫苗的 COVID-19 病例的重症结局风险降低。

Risk reduction of severe outcomes in vaccinated COVID-19 cases: an analysis of surveillance data from Estonia, Ireland, Luxembourg and Slovakia, January to November 2021.

机构信息

European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.

Republic of Estonia Health Board, Tallinn, Estonia.

出版信息

Euro Surveill. 2022 Feb;27(7). doi: 10.2807/1560-7917.ES.2022.27.7.2200060.

DOI:10.2807/1560-7917.ES.2022.27.7.2200060
PMID:35177166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8855507/
Abstract

Despite high COVID-19 vaccine coverage in the EU/EEA, there are increasing reports of SARS-CoV-2 infections and hospitalisations in vaccinated individuals. Using surveillance data from Estonia, Ireland, Luxembourg and Slovakia (January-November 2021), we estimated risk reduction of severe outcomes in vaccinated cases. Increasing age remains the most important driver of severity, and vaccination significantly reduces risk in all ages for hospitalisation (adjusted relative risk (aRR): 0.32; 95% confidence interval (CI): 0.26-0.39) and death (aRR: 0.20; 95% CI: 0.13-0.29).

摘要

尽管欧盟/欧洲经济区的 COVID-19 疫苗接种率很高，但越来越多的报告显示接种疫苗的个体中仍有 SARS-CoV-2 感染和住院病例。我们使用来自爱沙尼亚、爱尔兰、卢森堡和斯洛伐克的监测数据（2021 年 1 月至 11 月），估算了接种疫苗者发生严重后果的风险降低情况。年龄增长仍是严重程度的最重要驱动因素，而疫苗接种在各年龄段均显著降低了住院（校正相对风险[aRR]：0.32；95%置信区间[CI]：0.26-0.39）和死亡（aRR：0.20；95% CI：0.13-0.29）的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5394/8855507/7a8fee808fd8/2200060-fa.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5394/8855507/7a8fee808fd8/2200060-fa.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5394/8855507/7a8fee808fd8/2200060-fa.jpg

相似文献

1
Risk reduction of severe outcomes in vaccinated COVID-19 cases: an analysis of surveillance data from Estonia, Ireland, Luxembourg and Slovakia, January to November 2021.2021 年 1 月至 11 月，爱沙尼亚、爱尔兰、卢森堡和斯洛伐克的监测数据分析显示，接种疫苗的 COVID-19 病例的重症结局风险降低。
Euro Surveill. 2022 Feb;27(7). doi: 10.2807/1560-7917.ES.2022.27.7.2200060.
2
Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland.评估 SARS-CoV-2 感染严重形式的真实世界疫苗有效性：来自瑞士常规监测数据的观察性研究。
Swiss Med Wkly. 2022 Apr 19;152:w30163. doi: 10.4414/smw.2022.w30163. eCollection 2022 Apr 11.
3
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.在以色列全国范围内使用辉瑞-生物科技公司的 BNT162b2 mRNA COVID-19 疫苗进行疫苗接种运动，以预防感染、住院和死亡：一项回顾性监测研究。
Lancet Infect Dis. 2022 Mar;22(3):357-366. doi: 10.1016/S1473-3099(21)00566-1. Epub 2021 Sep 22.
4
Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.当在丹麦将第一剂 ChAdOx1 疫苗与随后的 mRNA 疫苗相结合时，针对 SARS-CoV-2 感染、住院和死亡的疫苗有效性：一项全国范围内基于人群的队列研究。
PLoS Med. 2021 Dec 17;18(12):e1003874. doi: 10.1371/journal.pmed.1003874. eCollection 2021 Dec.
5
SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.2021 年 5 月 1 日至 7 月 25 日，加利福尼亚州洛杉矶县≥16 岁人群中，根据疫苗接种状况划分的 SARS-CoV-2 感染和住院情况。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176. doi: 10.15585/mmwr.mm7034e5.
6
Initial assessment of the COVID-19 vaccination's impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021.2020 年 12 月至 2021 年 5 月，15 个欧盟/欧洲经济区国家 80 岁及以上人群中 COVID-19 疫苗接种对病例数量、住院和死亡的初步评估。
Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2101030.
7
Prevalence of antibodies to SARS-CoV-2 in Irish hospital healthcare workers.爱尔兰医院医护人员中 SARS-CoV-2 抗体的流行情况。
Epidemiol Infect. 2021 Apr 27;149:e157. doi: 10.1017/S0950268821000984.
8
Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021.基于真实世界监测数据估计的 COVID-19 疫苗对严重急性呼吸道感染（SARI）相关住院的有效性，斯洛文尼亚，2021 年 10 月。
Euro Surveill. 2022 Jan;27(1). doi: 10.2807/1560-7917.ES.2022.27.1.2101110.
9
Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.2021 年 1 月至 9 月，九个州感染诱导或 mRNA 疫苗诱导的 SARS-CoV-2 免疫的具有 COVID-19 样疾病住院成人的实验室确诊 COVID-19。
MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1539-1544. doi: 10.15585/mmwr.mm7044e1.
10
Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England.BNT162b2 mRNA 疫苗对老年人 COVID-19 感染和住院的影响：英格兰配对病例对照研究。
BMC Med. 2021 Oct 18;19(1):275. doi: 10.1186/s12916-021-02149-4.

引用本文的文献

1
Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination.由新冠病毒感染或新冠疫苗接种诱导产生的中和抗体所识别的表位之间的差异。
iScience. 2023 Jun 25;26(7):107208. doi: 10.1016/j.isci.2023.107208. eCollection 2023 Jul 21.
2
The Role of Vaccination and Face Mask Wearing on COVID-19 Infection and Hospitalization: A Cross-Sectional Study of the MENA Region.接种疫苗和佩戴口罩对新冠病毒感染及住院治疗的作用：中东和北非地区的一项横断面研究
Healthcare (Basel). 2023 Apr 28;11(9):1257. doi: 10.3390/healthcare11091257.
3
Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.

本文引用的文献

1
Initial assessment of the COVID-19 vaccination's impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021.2020 年 12 月至 2021 年 5 月，15 个欧盟/欧洲经济区国家 80 岁及以上人群中 COVID-19 疫苗接种对病例数量、住院和死亡的初步评估。
Euro Surveill. 2021 Dec;26(48). doi: 10.2807/1560-7917.ES.2021.26.48.2101030.
2
Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021.根据 2020 年 12 月至 2021 年 11 月期间在世界卫生组织欧洲区域内，60 岁及以上人群因接种 COVID-19 疫苗而直接避免的死亡人数估计数。
Euro Surveill. 2021 Nov;26(47). doi: 10.2807/1560-7917.ES.2021.26.47.2101021.
3
西班牙纳瓦拉 2022 年 1 月至 3 月，在 SARS-CoV-2 变异株奥密克戎 BA.1 为主的流行期间，接种疫苗的 COVID-19 病例住院和重症疾病风险降低。
Euro Surveill. 2023 Feb;28(5). doi: 10.2807/1560-7917.ES.2023.28.5.2200337.
4
Impact of COVID-19 vaccination in post-COVID cardiac complications.COVID-19 疫苗接种对新冠后心脏并发症的影响。
Vaccine. 2023 Feb 17;41(8):1524-1528. doi: 10.1016/j.vaccine.2023.01.052. Epub 2023 Jan 27.
5
COVID-19: Relative Risk of Non-Vaccinated to Vaccinated Individuals.新冠病毒病（COVID-19）：未接种疫苗者与接种疫苗者的相对风险
Diseases. 2022 Nov 23;10(4):113. doi: 10.3390/diseases10040113.
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.与 SARS-CoV-2 突破性感染相关的时间。
Nat Commun. 2021 Nov 4;12(1):6379. doi: 10.1038/s41467-021-26672-3.
4
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.COVID-19 疫苗对 Delta（B.1.617.2）变异株感染的有效性：2021 年 1 月 1 日至 8 月 25 日期间一项实时系统评价和荟萃分析的第二次中期结果。
Euro Surveill. 2021 Oct;26(41). doi: 10.2807/1560-7917.ES.2021.26.41.2100920.
5
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.以色列全国疫苗接种运动后，mRNA BNT162b2疫苗对SARS-CoV-2感染及COVID-19病例、住院和死亡的影响与效果：一项利用国家监测数据的观察性研究
Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5.
6
First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020.2020 年 1 月 24 日至 2 月 21 日，世卫组织欧洲区域出现 2019 冠状病毒病（COVID-19）首例病例。
Euro Surveill. 2020 Mar;25(9). doi: 10.2807/1560-7917.ES.2020.25.9.2000178.